8-K: Lantheus Reports Blockbuster Year: PYLARIFY Sales Exceed $1 Billion, Strategic Acquisitions Position Company for Future Growth

Lantheus Holdings announces strong fourth quarter and full-year 2024 results, highlighted by PYLARIFY achieving blockbuster status and strategic acquisitions to diversify its portfolio.

Summary

• Lantheus Holdings reported its fourth quarter and full year 2024 financial results.
• Worldwide revenue for Q4 2024 increased by 10.5% to $391.1 million compared to the same period in 2023.
• Full year 2024 worldwide revenue reached $1.53 billion.
• PYLARIFY sales exceeded $1 billion, reaching $266.0 million in Q4 2024, a 15.7% increase, and $1.057 billion for the full year, a 24.3% increase.
• DEFINITY sales increased by 17.9% to $86.2 million in Q4 2024 and 13.6% to $317.792 million for the full year.
• GAAP fully diluted loss per share was $(0.17) for Q4 2024, compared to earnings per share of $1.47 in the prior year period.
• GAAP fully diluted earnings per share was $4.36 for the full year 2024.
• Adjusted fully diluted earnings per share was $1.59 for Q4 2024 and $6.76 for the full year 2024.
• Free cash flow was $141.4 million for Q4 2024 and $493.1 million for the full year 2024.
• The company announced several strategic asset and in-licensing deals to diversify its portfolio.
• Lantheus provided full year 2025 revenue guidance of $1.545 billion $1.610 billion and adjusted fully diluted EPS guidance of $7.00 $7.20.
• The company repurchased approximately $100.0 million of common stock during the fourth quarter at an average price of $89.59 per share.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, a blockbuster product, and strategic acquisitions. While there are some negative aspects like the GAAP loss per share for Q4, the overall tone is optimistic and suggests a promising future for the company.

Positives

• PYLARIFY achieved blockbuster status, exceeding $1 billion in net sales.
• Worldwide revenue increased by 10.5% in Q4 2024.
• DEFINITY sales increased by 17.9% in Q4 2024.
• Net cash provided by operating activities increased 40.5% to $157.7 million in Q4 2024.
• Free cash flow increased 41.1% to $141.4 million in Q4 2024.
• Cash and cash equivalents grew to $912.8 million at the end of 2024.
• The company has access to up to $750.0 million from a revolving line of credit.
• Strategic acquisitions and in-licensing deals are expected to diversify the company's portfolio.
• CMS released its final Medicare Hospital Outpatient Prospective Payment System (OPPS) rule for calendar year 2025 which included separate payment for specialized diagnostic radiopharmaceuticals.
• The company announced the addition of two new members to the Board of Directors.
• The company repurchased approximately $100.0 million of common stock during the fourth quarter at an average price of $89.59 per share.

Negatives

• GAAP fully diluted loss per share was $(0.17) for Q4 2024, compared to earnings per share of $1.47 in the prior year period.
• Operating income decreased 17.2% to $113.9 million in Q4 2024.
• Adjusted operating income decreased 8.4% to $151.8 million in Q4 2024.
• Strategic Partnerships and other revenue decreased (66.2)% in Q4 2024.

Risks

• Continued market expansion and penetration for PYLARIFY and DEFINITY in a competitive environment is subject to risk.
• The company's ability to manufacture products and product candidates is subject to risk.
• Availability of raw materials, key components, and equipment is subject to risk.
• The company's ability to satisfy obligations under existing clinical development partnerships and license agreements is subject to risk.
• The company's ability to secure necessary shareholder and regulatory approvals relating to potential acquisitions is subject to risk.
• The cost, efforts and timing for clinical development, regulatory approval, adequate coding, coverage and payment and successful commercialization of product candidates are subject to risk.
• The company's ability to identify opportunities to collaborate with strategic partners and to acquire or in-license additional diagnostic and therapeutic product opportunities is subject to risk.

Future Outlook

Lantheus expects full year 2025 revenue to be between $1.545 billion and $1.610 billion and adjusted fully diluted EPS to be between $7.00 and $7.20.

Management Comments

• 2024 was a groundbreaking year for Lantheus, as our radiodiagnostic, PYLARIFY, reached blockbuster status, and we enhanced our radiopharmaceutical leadership, said Brian Markison, Chief Executive Officer at Lantheus.
• In 2025, we will grow our commercial portfolio, advance several earlyand late-stage clinical assets, expand our pipeline and end-to-end capabilities, and most importantly, provide innovative radiopharmaceutical solutions to deliver better patient outcomes.
• We will continue to execute a thoughtful strategy to diversify our portfolio and pipeline and concentrate on attractive markets with significant potential to create long-term sustainable growth and shareholder value.

Industry Context

Lantheus is positioning itself as a leader in the radiopharmaceutical market through strategic acquisitions and a focus on innovative diagnostic and therapeutic solutions, particularly in oncology and neurology. The company's focus on radiopharmaceuticals aligns with the growing trend of targeted therapies and personalized medicine.

Comparison to Industry Standards

• PYLARIFY's blockbuster status places Lantheus among the top players in the radiopharmaceutical diagnostics market.
• The company's strategic acquisitions of Life Molecular and Evergreen Theragnostics are similar to moves made by other large pharmaceutical companies to expand their pipelines and capabilities in specialized areas.
• Lantheus's focus on Alzheimer's disease diagnostics with assets like NAV-4694 and MK-6240 aligns with the industry's increasing investment in neurodegenerative disease research, similar to companies like Biogen and Eli Lilly.
• The company's revenue growth and profitability metrics are competitive with other radiopharmaceutical companies, such as Curium and Telix Pharmaceuticals.

Management Changes

Stakeholder Impact

• Shareholders can expect continued growth and value creation through strategic acquisitions and product development.
• Employees will benefit from the company's expansion and investment in new technologies.
• Patients will have access to innovative radiopharmaceutical solutions for better disease management.
• The company's financial stability and growth will positively impact suppliers and creditors.

Next Steps

• Close the acquisitions of Life Molecular and Evergreen Theragnostics in the second half of 2025.
• Continue to develop and commercialize existing products and product candidates.
• Advance earlyand late-stage clinical assets.
• Expand the company's pipeline and end-to-end capabilities.
• Repurchase additional shares of common stock under the authorized program.

Key Dates